Keyword: Hanmi Pharmaceutical
Hanmi Pharmaceutical’s long and turbulent development of lung cancer drug olmutinib finally came to an end this week.
Korean authorities say that Hanmi Pharmaceutical was too slow in revealing a side effect that later caused a fatality in the test of its lung cancer med olmutinib.
Boehringer has backed out of the $730 million lung cancer pact it struck with Hanmi Pharmaceutical after reviewing the data and competitive landscape.
Roche’s Genentech is pairing up with Hanmi Pharmaceutical to gain access to its Phase I pan-RAF inhibitor.